InvestorsHub Logo
Followers 30
Posts 2699
Boards Moderated 0
Alias Born 01/23/2010

Re: None

Sunday, 03/26/2017 9:18:53 AM

Sunday, March 26, 2017 9:18:53 AM

Post# of 18220
IMUN acquired the patents for IRT-101 and IRT-103 from Cytocom. In the Investor Presentation Cytocom presented both IRT-101 and IRT-103 in various stages of clinical trials. See the link to the presentation. They presented a view of the phase trials being very successful. I've searched trying to find what happened next. I have to wonder why if there is so much promise in the formulations why it didn't go to the next phase in the trials. Can anyone explain why this didn't happen?

http://www.cytocom.com/investors/